Holen Sie sich die Stockscreener-App
228.12
1.51%
3.40
Vorhandelsmarkt:
222.76
-5.36
-2.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$224.72
Offen:
$226.09
24-Stunden-Volumen:
1.17M
Relative Volume:
1.07
Marktkapitalisierung:
$33.23B
Einnahmen:
$5.40B
Nettoeinkommen (Verlust:
$1.49B
KGV:
22.55
EPS:
10.1168
Netto-Cashflow:
$1.78B
1W Leistung:
-0.33%
1M Leistung:
-2.30%
6M Leistung:
-14.91%
1J Leistung:
+7.14%
1-Tages-Spanne:
$225.47
$230.03
1-Wochen-Bereich:
$223.79
$232.32
52-Wochen-Spanne:
$209.31
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
228.12 | 33.23B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
469.21 | 166.65B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.54 | 45.10B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
81.32 | 39.64B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
47.64 | 38.67B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
JPMorgan Issues Overweight Rating for ResMed Amid Sleep Apnea Shift - HarianBasis.co
JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT - Yahoo Finance
Lbp Am Sa Buys 18,142 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Should you continue to hold Resmed stock in your portfolio? - MSN
Should You Continue to Hold Resmed Stock in Your Portfolio? - Yahoo Finance
KBC Group NV Has $57.23 Million Position in ResMed Inc. $RMD - MarketBeat
Hendershot Investments Inc. Increases Holdings in ResMed Inc. $RMD - MarketBeat
Mizuho Maintains ResMed Inc.Depositary Receipt (RSMDF) Outperform Recommendation - MSN
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
INVESCO V.I. Health Care Fund's ResMed Inc(RMD) Holding History - GuruFocus
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares? - The Motley Fool Australia
ResMed Inc. stock (US7611521078): Why does its sleep apnea dominance matter more now? - AD HOC NEWS
ResMed (NYSE:RMD) Now Covered by JPMorgan Chase & Co. - MarketBeat
Baird Adjusts Price Target on ResMed to $254 From $272, Maintains Neutral Rating - marketscreener.com
ResMed Inc. $RMD Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
ResMed Inc. stock (US7611521078): Is sleep apnea market growth strong enough to unlock new upside? - AD HOC NEWS
ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
RMD Analyst Rating Maintained at Outperform by Evercore ISI - Meyka
ResMed Inc (NYSE:RMD): A Durable Dividend Growth Stock for Passive Income - ChartMill
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Ord Minnett - The Globe and Mail
Wells Fargo Analyst Raises ResMed (RMD) Price Target to $270 | R - GuruFocus
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Trade Ideas — LSX:935168 - TradingView
ResMed Faces Shifting Market Signals in Healthcare Space - Kalkine Media
ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares - MarketBeat
Citigroup Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - MarketBeat
Resmed CEO Farrell sells $1.12 million in stock - Investing.com
Resmed CEO Farrell sells $1.12 million in stock By Investing.com - Investing.com Australia
ResMed (RMD) CEO Farrell sells 4,991 shares after option exercise - Stock Titan
ResMed Insider Selling Raises Questions On Management Conviction And Valuation - Sahm
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
Citigroup Adjusts Price Target on ResMed to $340 From $345, Maintains Buy Rating - marketscreener.com
ResMed Inc. $RMD Shares Sold by Pacific Point Advisors LLC - MarketBeat
ResMed CEO Michael Farrell Plans Additional Insider Sale Under Rule 144 - TipRanks
Affiliate plans sale of 4,991 RMD shares via Fidelity (NYSE: RMD) - Stock Titan
Is Now The Time To Put ResMed (NYSE:RMD) On Your Watchlist? - Moomoo
Robinhood Asset Management Boosts ResMed Stake - National Today
Sleep Apnea Devices Market to Reach Strong Growth Through 2033 - openPR.com
ResMed Adjusts CDI and Share Balances Amid Transfers, Equity Issuance and Buybacks - TipRanks
ResMed Officer Sandercock Discloses Ongoing Insider Share Sales Under Rule 144 - TipRanks
4,837 Shares in ResMed Inc. $RMD Acquired by Runnymede Capital Advisors Inc. - MarketBeat
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
Wealth Enhancement Advisory Services LLC Has $1.66 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Element Squared LLC Buys Shares of 6,067 ResMed Inc. $RMD - marketbeat.com
Aberdeen Group Reduces Stake in ResMed Inc. - National Today
Aberdeen Group plc Sells 37,737 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
RESMED INC. R (RME.MU) Q1 FY2025 earnings call transcript - Yahoo Finance
Resmed CFO Sandercock sells $224k in stock By Investing.com - Investing.com South Africa
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):